IPO Timeline
Broker Results (T-2)
2021-07-09
Some brokers release in afternoon
Grey Market (T-1)
2021-07-12
Afternoon
HKEX Allotment (T-1)
2021-07-12
Evening
Registrar Allotment (T-1)
2021-07-12
Evening
Listing Day (T)
2021-07-13
First day of trading
Company Overview
| Stock Name | 騰盛博藥生物科技有限公司 - B |
|---|---|
| Stock Code | 02137 |
| Company Full Name | 騰盛博藥生物科技有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於研發傳染病療法。 |
| Listing Date | 2021-07-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市海淀區永泰莊北路1號中關村東升國際科學園7號樓3層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.briibio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 22.25 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 47.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,241,327,500 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 22.95 |
|---|---|
| First Day Open | HK$ 21.4 |
| First Day Change | 3.15% |
| First Day Volume | 67365100.0 |
| First Day Turnover | 1507880000.0 |
Use of Proceeds
| Use of Proceeds | 1、55%（約1,283.6百萬港元）將劃撥至HBV功能性治愈項目； 2、15%（約350.1百萬港元）預期將劃撥至HIV項目，用于為BRII-778和BRII-732正在進行及計劃的臨床試驗及登記備案準備提供資金； 3、15%（約350.1百萬港元）將劃撥至MDR/XDR革蘭氏陰性菌感染項目； 4、5%（約116.7百萬港元）將用于為BRII-296正在進行及計劃的臨床試驗及登記備案準備提供資金； 5、10%（約233.4百萬港元）將劃撥至我們的早期階段管線、業務發展計劃、營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (3)
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 77,619,125 HKD | — | 3.13% | — | 6 months | 2022-01-13 |
| 2 | Athos Asia Event Driven Master Fund | 38,804,000 HKD | — | 1.56% | — | 6 months | 2022-01-13 |
| 3 | Boyu Capital Opportunities Master Fund | 38,804,000 HKD | — | 1.56% | — | 6 months | 2022-01-13 |
| 4 | Invesco Advisers, Inc. | 310,509,875 HKD | — | 12.51% | — | 6 months | 2022-01-13 |
| 5 | Sage Partners Master Fund | 38,804,000 HKD | — | 1.56% | — | 6 months | 2022-01-13 |
| 6 | SCC Growth V Holdco Q, Ltd. | 15,519,375 HKD | — | 0.63% | — | 6 months | 2022-01-13 |
| 7 | Springhill Master Fund Limited | 77,619,125 HKD | — | 3.13% | — | 6 months | 2022-01-13 |
| 8 | The Valliance Fund | 38,804,000 HKD | — | 1.56% | — | 6 months | 2022-01-13 |
| 9 | UBS Asset Management (Singapore) Ltd. | 271,694,750 HKD | — | 10.94% | — | 6 months | 2022-01-13 |
| 10 | 加皇环球资产管理(亚洲)有限公司 | 232,879,625 HKD | — | 9.38% | — | 6 months | 2022-01-13 |
| 11 | 有鱼环球有限公司 | 38,804,000 HKD | — | 1.56% | — | 6 months | 2022-01-13 |
Directors & Management
| Chairman | Zhi HONG |
|---|---|
| Company Secretary | 李安康;何詠紫 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Boyu Capital Group Holdings Ltd (15.48%);ARCH Venture Partners IX, LLC(12.51%)Yunfeng Fund III, L.P.(7.40%);Invesco Advisers, Inc.(6%) |
|---|
IPO Timeline
